In 2020, when Moderna announced a vaccine that was 94.5% effective against Covid-19 in less than a year of development, scientists were stunned. Most thought that developing a vaccine would take five to ten years. Stéphane Bancel, Moderna's CEO, an engineer from Centrale Paris with an MBA from Harvard, had bet on a technology that no one wanted to fund ten years earlier. He was right.
Stéphane Bancel at Centrale Paris: from Marseille to chemical engineering labs
Stéphane Bancel was born on July 20, 1972 in Marseille into a French-Spanish family. His father was an engineer, his mother an occupational physician. He attended the École de Provence, then entered the preparatory classes at the Lycée Sainte-Geneviève in Versailles – Ginette, in the jargon of preparatory classes – one of the most selective in France in the scientific stream.
He entered Centrale Paris – now CentraleSupélec – in 1992 and graduated in 1995 with a specialization in chemical and biomolecular engineering. Simultaneously, he completed a dual-degree program at the University of Minnesota to further his training in chemistry. This choice of specialization was not insignificant: at the time, molecular biology was just beginning to enter the industrial world. Bancel perceived something that many engineers of his generation had yet to see.
What Centrale provides him is systemic rigor – the ability to reason about complex processes, to optimize production chains, to translate fundamental science into scalable industrial processes. This is precisely what he will need to transform research on messenger RNA into vaccines produced in the hundreds of millions of doses.
Read more: Jean-Pascal Tricoire, CentraleSupélec, CEO of Schneider Electric – Alumnow
BioMérieux and Harvard: Bancel learns business after engineering
Upon graduating from Centrale in 1995, Bancel joined BioMérieux, a Lyon-based group specializing in medical diagnostics, as Marketing and Sales Director for the Asia-Pacific region in Japan. He spent three years fully immersed in a foreign market, selling diagnostic equipment to Japanese hospitals. There, he says, he discovered a taste for business – and decided to pursue it seriously.
In 1999, he enrolled in the MBA program at Harvard Business School, graduating in 2000. His time at Harvard didn't transform him into a financier—he remained fundamentally an engineer. But it provided him with a conceptual framework for thinking about corporate strategy, fundraising, and building a large-scale organization. The combination of Centrale and Harvard would be the foundation for everything that followed.
He then joined Eli Lilly & Co., the American pharmaceutical giant, where he quickly rose through the ranks. In less than four years, he went from supply chain manager to managing director for Belgium, overseeing 22,000 people across 23 sites. In 2007, BioMérieux brought him back as deputy managing director – he was 34 years old. He was the youngest CEO of a company of that size in France at the time.
Read more: Bernard Arnault, École Polytechnique, CEO of LVMH – Alumnow
Moderna in 2011: a bet on a technology that nobody wanted
In 2011, the venture capital fund Flagship Ventures approached Bancel. It had just invested $40 million in a fledgling American startup called Moderna, which was developing therapies based on messenger RNA – a technology that had yet to result in an approved product. Bancel agreed to take over as CEO.
The gamble is risky. mRNA is unstable, difficult to administer, and rejected by the immune system. Renowned scientists believe it will never work as a drug. Moderna raises funds nonetheless, attracts researchers, and accumulates patents. For eight years, the company has no product on the market. It survives on its fundraising and partnerships—notably with AstraZeneca in 2013 and Merck in 2016.
What Bancel brings to Moderna is the ability to industrialize. mRNA can be understood biologically. Manufacturing it in billions of doses under sterile conditions, with a controlled cold chain, in compressed timeframes – that's where an engineer from Centrale, trained in complex processes, makes the difference.
Read more: Patrick Pouyanné, Polytechnique, CEO of TotalEnergies – Alumnow
The Covid-19 vaccine and wealth: two years that changed everything
In January 2020, two days after China published the genetic sequence of SARS-CoV-2, Moderna began working on a vaccine. In November 2020, the results of the phase 3 clinical trials were released: 94.5% efficacy. The vaccine was authorized in the United States on December 18, 2020. Less than eleven months elapsed between the start of development and authorization. This is unprecedented in the history of vaccinology.
Moderna's stock price skyrockets. Bancel, who owns more than 5% of the company, sees his fortune reach several billion dollars in 2021. He enters Forbes' rankings of French billionaires. This meteoric rise will be followed by an equally spectacular fall: by 2025, with Moderna's stock price gradually collapsing to $25, his fortune has plummeted to approximately $1.2 billion. The volatility of biotech, in all its brutality.
Moderna is now working on mRNA vaccines against influenza, HIV, and certain cancers. The technology has proven effective. The question now is how far it can go. For Stéphane Bancel and his team, the answer is: much further than a Covid-19 vaccine.
Frequently asked questions about Stéphane Bancel
Which school did Stéphane Bancel attend?
Stéphane Bancel graduated from Centrale Paris (now CentraleSupélec) in 1995, specializing in chemical and biomolecular engineering. He also spent a year at the University of Minnesota and earned an MBA from Harvard Business School in 2000.
How did Stéphane Bancel come to head Moderna?
In 2011, Flagship Ventures offered him the opportunity to lead Moderna, a startup developing messenger RNA therapies. Bancel accepted after a career at BioMérieux and Eli Lilly. He has led the company ever since, overseeing the development of the Covid-19 vaccine authorized in December 2020.
What is Stéphane Bancel's net worth?
Stéphane Bancel's fortune reached several billion dollars in 2021, fueled by the surge in Moderna's stock price during the Covid-19 pandemic. By 2025, with the stock price expected to fall, it is estimated at around $1.2 billion. He owns more than 5% of Moderna's capital.







